Cannabis Funds Lose Momentum
ETF Central | Nov 01, 2023 10:05AM ET
Cannabis assets appeared to be in freefall over the past week. No longer propelled by the earlier momentum that followed calls from the Department of Health and Human Services (HSS) to review cannabis classification, companies aligned with the industry have succumbed to market pressures.
Late August saw an appeal put forward to the Drug Enforcement Administration (DEA) calling for a reevaluation of marijuana's classification from its current Schedule I status - where it is grouped with substances such as LSD and heroin - to reclassification as a Schedule III drug, in line with substances such as ketamine and testosterone. This shift would also serve to remove cannabis from the list of substances considered devoid of medical value.
Such as move could have far-reaching implications, including helping to reduce perceived stigma around cannabis use, particularly for medical reasons. Interestingly, marijuana currently carries a higher perceived risk than fentanyl under its Schedule I classification - despite the high number of fentanyl-associated fatalities across the U.S. This skewed positioning underscores another strong reason to favor reclassification.
Given the support shown by the HSS – and the significance of such a move - cannabis stocks predictably skyrocketed, buoyed by the potential opportunities of an industry on the brink of mainstream acceptance.
Last week struck a deafening blow to any such optimism, however. Against the S&P 500 benchmark index that had already fallen by 2.21% for the week, ETFs focused on cannabis & psychedelics plunged more than 17%.
As an example, AdvisorShares Pure US Cannabis ETF (MSOS) witnessed a punishing week-over-week decline of 22.45%.
h2 Segment Data: Cannabis & Psychedelics/h2This content was originally published by our partners at ETF Central .
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.